Sign Up Today and Learn More About Q Bio Stock
Invest in or calculate the value of your shares in Q Bio or other pre-IPO companies through EquityZen's platform.
Q Bio Stock (QBIO)
On a mission to build the first Clinical Digital Twin Platform and make it accessible to everyone
About Q Bio Stock
Founded
2015
Headquarters
San Carlos, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Q Bio was founded in 2015 by Jeffrey Kaditz, serial entrepreneur and Founder of Affirm, Dr Michael Snyder, Chair of Genetics and Director of Personalized Medicine and Stanford University, and Dr Garry Choy, physician, radiologist, and former Chief Medical Information Officer at Mass General Hospital. Q Bio is fortunate to be backed by some of the best venture groups in the world including: A16Z, Khosla Ventures, Founders Fund, SciFi VC, and Kevin Durant. This interdisciplinary team based in San Carlos, CA is comprised of pioneers in fields such applied math, computational physics, electrical engineering, genetics, and radiology, hail from a dizzying array of home countries and cultural backgrounds.
Q Bio Press Mentions
Stay in the know about the latest news on Q Bio
What the Trump administration means for corporate venturers
globalventuring • Jan 22, 2025
The Scientist Announces Its 2024 Top 10 Innovations Winners
prweb • Dec 17, 2024
Startup Q Bio raises $27 million to build its own full-body scanner
statnews • Aug 04, 2024
Clarissa Shen’s Post
linkedin • Aug 04, 2024
Q Bio Unveils New MRI Technology - Tensor Field Mapping - Advancing Measurement in Medical Imaging
businesswire • Jun 04, 2024
Q Bio Management
Leadership team at Q Bio
Founder, CEO & CTO
Jeffrey Kaditz
COO
Clarissa Shen
Join now and verify your accreditation status to gain access to:
- Q Bio Current Valuation
- Q Bio Stock Price
- Q Bio Management
- Available deals in Q Bio and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Q Bio Cap Table and Funding History by Share Class and Liquidity Preferences
- Q Bio Revenue and Financials
- Q Bio Highlights
- Q Bio Business Model
- Q Bio Risk Factors
- Q Bio Research Report from SACRA Research
Trading Q Bio Stock
How to invest in Q Bio stock?
Accredited investors can buy pre-IPO stock in companies like Q Bio through EquityZen funds. These investments are made available by existing Q Bio shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Q Bio stock?
Shareholders can sell their Q Bio stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
